Bank of New York Mellon Corp
BankPosition in CATX — Perspective Therapeutics, Inc.
CIK 1390777
NEW YORK, NY
Position in CATX
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$772,846
+$254,183 QoQ
Shares Held
185,335
-1.7% QoQ
Ownership
0.163%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 79%
Shared 0%
None 21%
Common Shares in CATX Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Mar 31, 2026Bank of New York Mellon Corp holds $7,060,002,395 across 86 Medical Devices names. CATX ranks #55 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDT |
Medtronic plc
|
15,501,869 | $1,343,236,934 | |
| 2 | EW |
Edwards Lifesciences Corp
|
16,737,548 | $1,340,342,829 | |
| 3 | SYK |
Stryker Corp
|
3,952,401 | $1,298,719,433 | |
| 4 | ABT |
Abbott Laboratories
|
12,442,717 | $1,277,493,746 | |
| 5 | BSX |
Boston Scientific Corp
|
9,543,875 | $598,878,148 | |
| 6 | GEHC |
GE HealthCare Technologies Inc.
|
2,819,912 | $200,721,327 | |
| 7 | DXCM |
Dexcom Inc
|
2,143,141 | $134,589,248 | |
| 8 | STE |
STERIS plc
|
524,508 | $115,984,445 |
All Filings in CATX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $772,846 | 185,335 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $518,663 | 188,605 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $649,459 | 189,347 | Shares | Defined | 2025-11-03 | |
| 2025-06-30 | $617,853 | 179,609 | Shares | Defined | 2025-08-05 | |
| 2025-03-31 | $339,448 | 159,366 | Shares | Defined | 2025-04-29 | |
| 2024-12-31 | $457,665 | 143,469 | Shares | Defined | 2025-02-04 | |
| 2024-09-30 | $1,852,659 | 138,776 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $1,368,561 | 137,268 | Shares | Defined | 2024-07-25 | |
| No filing history on record for this holder in this stock. | ||||||